CL2017002677A1 - Método para incrementar el porcentaje de anticuerpos monoméricos fab-dsfv de especies multiméricas - Google Patents

Método para incrementar el porcentaje de anticuerpos monoméricos fab-dsfv de especies multiméricas

Info

Publication number
CL2017002677A1
CL2017002677A1 CL2017002677A CL2017002677A CL2017002677A1 CL 2017002677 A1 CL2017002677 A1 CL 2017002677A1 CL 2017002677 A CL2017002677 A CL 2017002677A CL 2017002677 A CL2017002677 A CL 2017002677A CL 2017002677 A1 CL2017002677 A1 CL 2017002677A1
Authority
CL
Chile
Prior art keywords
percentage
increase
multimeric species
monomeric fab
species
Prior art date
Application number
CL2017002677A
Other languages
English (en)
Spanish (es)
Inventor
Sam Philip Heywood
Gavin Barry Wild
Razwan Hanif
Page Christopher John Le
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of CL2017002677A1 publication Critical patent/CL2017002677A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CL2017002677A 2015-04-22 2017-10-20 Método para incrementar el porcentaje de anticuerpos monoméricos fab-dsfv de especies multiméricas CL2017002677A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1506869.5A GB201506869D0 (en) 2015-04-22 2015-04-22 Method

Publications (1)

Publication Number Publication Date
CL2017002677A1 true CL2017002677A1 (es) 2018-03-23

Family

ID=53299018

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017002677A CL2017002677A1 (es) 2015-04-22 2017-10-20 Método para incrementar el porcentaje de anticuerpos monoméricos fab-dsfv de especies multiméricas

Country Status (16)

Country Link
US (2) US10829565B2 (enExample)
EP (1) EP3286220A1 (enExample)
JP (1) JP6901402B2 (enExample)
KR (1) KR20170138551A (enExample)
CN (1) CN107683290B (enExample)
AU (1) AU2016251960A1 (enExample)
BR (1) BR112017022472A2 (enExample)
CA (1) CA2983537A1 (enExample)
CL (1) CL2017002677A1 (enExample)
CO (1) CO2017010845A2 (enExample)
EA (1) EA201792325A1 (enExample)
GB (1) GB201506869D0 (enExample)
IL (1) IL255094A0 (enExample)
MX (1) MX2017013419A (enExample)
SG (1) SG11201708430VA (enExample)
WO (1) WO2016170137A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201223276D0 (en) * 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
GB201506869D0 (en) * 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
GB201506868D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method for protein purification
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
RS61808B1 (sr) * 2016-12-09 2021-06-30 Ose Immunotherapeutics Antitela i polipeptidi usmereni protiv cd127

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
US4877868A (en) * 1986-03-12 1989-10-31 Neorx Corporation Radionuclide antibody coupling
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE768377T1 (de) 1988-09-02 1998-01-02 Dyax Corp Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
WO1992018619A1 (en) 1991-04-10 1992-10-29 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0733070A1 (en) 1993-12-08 1996-09-25 Genzyme Corporation Process for generating specific antibodies
EP1231268B1 (en) 1994-01-31 2005-07-27 Trustees Of Boston University Polyclonal antibody libraries
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
GB0202633D0 (en) * 2002-02-05 2002-03-20 Delta Biotechnology Ltd Stabilization of protein preparations
PT1570267E (pt) 2002-12-03 2012-01-03 Ucb Pharma Sa Ensaio para a identificação de células produtoras de anticorpos
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
US7989594B2 (en) 2003-07-01 2011-08-02 Celltech R & D Limited Modified antibody fab fragments
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315450D0 (en) * 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
CA2584211C (en) 2004-10-22 2014-07-08 Amgen Inc. Methods for refolding of recombinant antibodies
GB0425534D0 (en) * 2004-11-19 2004-12-22 Celltech R&D Ltd Process for obtaining antibodies
CN101583370A (zh) * 2005-09-27 2009-11-18 阿穆尼克斯公司 蛋白质药物及其用途
WO2007038619A2 (en) 2005-09-27 2007-04-05 Amunix, Inc. Proteinaceous pharmaceuticals and uses thereof
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
EP2014680A1 (en) 2007-07-10 2009-01-14 Friedrich-Alexander-Universität Erlangen-Nürnberg Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives
CA2700714C (en) 2007-09-26 2018-09-11 Ucb Pharma S.A. Dual specificity antibody fusions
US20090269343A1 (en) 2008-04-11 2009-10-29 Duke University Dual Specific Immunotoxin for Brain Tumor Therapy
AU2009282234A1 (en) 2008-08-14 2010-02-18 Merck Sharp & Dohme Corp. Methods for purifying antibodies using protein a affinity chromatography
AU2009296708A1 (en) * 2008-09-26 2010-04-01 Merck Sharp & Dohme Corp. High titer antibody production
PT2334705T (pt) * 2008-09-26 2017-03-22 Ucb Biopharma Sprl Produtos biológicos
WO2010125187A2 (en) * 2009-04-30 2010-11-04 Ablynx Nv Method for the production of domain antibodies
EP2475682B1 (en) 2009-09-10 2018-01-31 UCB Biopharma SPRL Multivalent antibodies
GB201005063D0 (en) * 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
GB0920127D0 (en) * 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
GB201001791D0 (en) * 2010-02-03 2010-03-24 Ucb Pharma Sa Process for obtaining antibodies
GB201005064D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
TR201903279T4 (tr) 2010-03-25 2019-03-21 Ucb Biopharma Sprl Disülfür stabilize edilmiş DVD-IG molekülleri.
US9150663B2 (en) * 2010-04-20 2015-10-06 Genmab A/S Heterodimeric antibody Fc-containing proteins and methods for production thereof
KR101860963B1 (ko) * 2010-04-23 2018-05-24 제넨테크, 인크. 이종다량체 단백질의 생산
WO2012140214A1 (en) 2011-04-13 2012-10-18 Biomay Ag IMMUNOAFFINITY SEPARATION MATERIALS COMPRISING ANTI-IgE ANTIBODY DERIVATIVES
JP6216321B2 (ja) 2011-10-11 2017-10-18 ジェネンテック， インコーポレイテッド 二重特異性抗体の構築の改善
UA112203C2 (uk) 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
MX351502B (es) * 2011-11-11 2017-10-18 Ucb Pharma Sa Anticuerpos de union de albumina y fragmentos de union de los mismos.
EP2822597A1 (en) 2012-03-09 2015-01-14 UCL Business Plc. Chemical modification of antibodies
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
GB201223276D0 (en) * 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
CN105764922B (zh) * 2013-09-27 2020-07-17 中外制药株式会社 多肽异源多聚体的制备方法
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
GB201506869D0 (en) * 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
GB201506868D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method for protein purification
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
PH12018500362B1 (en) 2015-08-17 2022-08-05 Lupin Ltd An improved refolding process for antibodys fragments

Also Published As

Publication number Publication date
US11834514B2 (en) 2023-12-05
EP3286220A1 (en) 2018-02-28
SG11201708430VA (en) 2017-11-29
CO2017010845A2 (es) 2018-03-20
MX2017013419A (es) 2018-02-09
IL255094A0 (en) 2017-12-31
KR20170138551A (ko) 2017-12-15
BR112017022472A2 (pt) 2018-07-17
EA201792325A1 (ru) 2018-04-30
US20210079120A1 (en) 2021-03-18
GB201506869D0 (en) 2015-06-03
CN107683290A (zh) 2018-02-09
CA2983537A1 (en) 2016-10-27
US20180142039A1 (en) 2018-05-24
JP6901402B2 (ja) 2021-07-14
JP2018515453A (ja) 2018-06-14
US10829565B2 (en) 2020-11-10
CN107683290B (zh) 2022-01-04
AU2016251960A1 (en) 2017-11-02
WO2016170137A1 (en) 2016-10-27

Similar Documents

Publication Publication Date Title
CL2017002677A1 (es) Método para incrementar el porcentaje de anticuerpos monoméricos fab-dsfv de especies multiméricas
PE20170665A1 (es) Anticuerpos anti-tau humanizados
AR113342A1 (es) Anticuerpos específicos cd47 / pd-l1
AR093803A1 (es) Composiciones y metodos de anticuerpos de marcaje de epo
EA201790377A1 (ru) Антитела к глюкагону и их применения
PE20180499A1 (es) Anticuerpos de union a tau
EA201491569A1 (ru) МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С СИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ
CU24597B1 (es) Anticuerpos biespecíficos heterodiméricos que se unen a cd3 y cd20
AR102239A1 (es) Anticuerpos anti-ox40 humanizados y sus usos
CL2017002676A1 (es) Método de monomerizacion de moléculas recombinantes de anticuerpo
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
MX394103B (es) Anticuerpos anti-angptl8 y usos de estos.
CO2017009060A2 (es) Polipéptido hibrido de la enzima de degradación inmunoglobulina g del s. pyogenes y enzima de degradación de inmunoglobulina g del streptococcus equi ssp. zooepidemicus
PE20181018A1 (es) Anticuerpos anti-pd-1 novedosos
CO2017005738A2 (es) Anticuerpos anti-pd-1
EA201591113A1 (ru) Антитела против антигена 2 дендритных клеток крови и их применение
PE20181805A1 (es) Composiciones y anticuerpos anti-tim-3
AR085600A1 (es) Agentes de union biespecifica
EA202091557A1 (ru) Антитела, содержащие только тяжелые цепи, которые связываются с cd22
EA201791270A1 (ru) Модифицированные april-связывающие антитела
EA201690167A1 (ru) Гуманизованные или химерные антитела к cd3
MX2023000738A (es) Proteinas de union a antigeno que activan el receptor de leptina.
MX360707B (es) Receptor antigénico quimérico.
EA201690325A1 (ru) БИСПЕЦИФИЧЕСКИЕ МОНОВАЛЕНТНЫЕ Fc-ДИАТЕЛА, КОТОРЫЕ СПОСОБНЫ СВЯЗЫВАТЬ CD32B И CD79b, И ИХ ПРИМЕНЕНИЯ
MX2015010599A (es) Anticuerpos dirigidos contra il-33 y sus usos.